SEC Tracker
Get the app

Estrella Immunopharma ESLA

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Form
8-K
Filed
Importance
Routine
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Estrella Immunopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Fibrogen FGEN public float $21M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. Imunon IMNN public float $21M, Jun 30, 2025
  4. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  5. Dare Bioscience DARE public float $21M, Jun 30, 2025